Article Figures & Data
Figures
- Figure 1.
Correlation analysis of sCTLA-4 serum levels with IFN-α, IL-10, and anti-dsDNA antibody titer in patients with SLE. A. IFN-α levels were measured by ELISA in serum from patients with SLE (n = 104) versus healthy volunteer donors (n = 40; *** p < 0.001; p values determined by nonparametric Mann-Whitney U test) using Mabtech human IFN-α ELISA development kit. B. Regression analysis of IFN-α (upper panel) and IL-10 (lower panel) with sCTLA-4 serum levels from patients with SLE (n = 104, Spearman rank analysis). C. Comparison of mean sCTLA-4 levels with anti-dsDNA autoantibody titer in serum samples from patients with SLE (n = 119). Error bars represent SD, horizontal bar indicates median. * p < 0.05. sCTLA-4: soluble T cell lymphocyte costimulation inhibitor; IFN: interferon; IL: interleukin; SLE: systemic lupus erythematosus.
- Figure 2.
Analysis of sCTLA-4, IFN-α, and IL-10 levels in serum and supernatant of patients with SLE segregated according to CT60 SNP genotype (A/A “resistant”, G/G “susceptible”; statistical values determined by nonparametric Kruskal-Wallis ANOVA with a Dunn’s multiple comparison post-test; median values are shown, * p < 0.05). Genomic DNA was extracted from 100 µl of whole blood using Qiagen DNeasy blood and tissue kit according to manufacturer’s instruction. SNP CT60 in the 3′ untranslated region (rs3087243) of the CTLA-4 gene were typed by allelic discrimination methods using TaqMan SNP assays (Applied Biosystems). sCTLA-4: soluble T cell lymphocyte costimulation inhibitor; SNP: single-nucleotide polymorphism; IFN: interferon; IL: interleukin; SLE: systemic lupus erythematosus.
